Drugs / LY-M003
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06650319 | Sep 2024 → Dec 2026 expected | Wilson disease | Chaohui Yu | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07641140 | Jun 2026 → Dec 2027 expected | Wilson disease | Lingyi Biotech Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY-M003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06650319 ↗ |
| Known as | LY-M003 Injection | “This is a multicenter, open-label, single-arm, single-dose Phase I/II clinical study. It aims to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacodynamic...” NCT07641140 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “LY-M003 Injection is a gene therapy products with rAAV8 vector.” NCT06650319 ↗ |
| Route | Intravenous | “single peripheral intravenous (IV) infusion of LY-M003” NCT06650319 ↗ |